Published in Acta Cardiol Sin on November 01, 2016
Protein Lipidation As a Regulator of Apoptotic Calcium Release: Relevance to Cancer. Front Oncol (2017) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2013) 5.57
Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation (2006) 4.35
Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia (2015) 3.28
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med (2015) 2.72
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant (2006) 2.50
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis (2005) 2.36
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol (2015) 2.33
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol (2013) 2.00
Statins and risk of polyneuropathy: a case-control study. Neurology (2002) 1.97
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med (2015) 1.74
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J (2011) 1.64
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis (2003) 1.63
Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst (2015) 1.58
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol (2014) 1.48
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf (2008) 1.03
Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients. J Gen Intern Med (2016) 0.97
Statin use and all-cancer survival: prospective results from the Women's Health Initiative. Br J Cancer (2016) 0.95
Safety of statins. Curr Opin Lipidol (2008) 0.94
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol (2010) 0.94
Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med (2003) 0.93
Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep (2014) 0.87
Intolerance to statins: mechanisms and management. Diabetes Care (2013) 0.87
Statins and the risk of interstitial lung disease: a cohort study. Thorax (2013) 0.84
Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther (2011) 0.83
Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther (2011) 0.81
Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. Cancer Med (2015) 0.79
The Effect of Intensified Low Density Lipoprotein Cholesterol Reduction on Recurrent Myocardial Infarction and Cardiovascular Mortality. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.78
Statin Dose and the Risk of Intracerebral Hemorrhage: A Population-Based Longitudinal Study in Taiwan. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.76